NCT06029036View on ClinicalTrials.gov

A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

August 5, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Darolutamide+ADT

"Drug: Darolutamide~Darolutamide 600 mg, (two 300 mg tablets) administered orally twice daily. Swallow tablets whole. Take Darolutamide with food.~Drug: ADT GnRH agonist per physicians' choice, orchiectomy is excluded"

Trial Locations (1)

Unknown

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER

collaborator

The First Affiliated Hospital of Air Force Medicial University

OTHER

lead

Peking University First Hospital

OTHER